Adile Orhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adile Orhan has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Ismail Gögenur
Department of Surgery, Centre for Surgical Science Zealand University Hospital Køge Denmark
15 shared publications Ismail Gögenur
Center for Surgical Science, Department of Surgery, Zealand University Hospital
11 shared publications- Hans Raskov
Center for Surgical Science, Zealand University Hospital, Køge, Denmark
9 shared publications - Michael Tvilling Madsen
Department of Surgery, Slagelse Hospital , Slagelse
7 shared publications - Tobias Freyberg Justesen
Department of Surgery, Center for Surgical Science, Zealand University Hospital, Køge, Denmark
5 shared publications Camilla Qvortrup
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
3 shared publications
Latest Publications
- Open Access
Safety and Feasibility of Endoscopic-Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: An Exploratory Randomised Clinical Trial
Background: Locally advanced rectal cancer (LARC) has high recurrence rates despite aggressive multimodal treatment with neoadjuvant chemoradiotherapy (CRT) followed by surgery. Electrochemotherapy (ECT), combining electroporation with chemotherapy, has shown safety and feasibility in other malignancies, but its role as an additive neoadjuvant treatment in rectal cancer remains unexplored. Methods: In this parallel-group, randomised safety and feasibility trial, patients with histologically verified LARC who completed neoadjuvant CRT were randomised 1:1 to a single ECT treatment with bleomycin before surgery (n = 8) or standard therapy (n = 8). The primary outcome was safety (amended from the protocol-specified efficacy endpoint after early study termination). Follow-up was scheduled before surgery and at 6 and 12 weeks post-surgery, including adverse events, clinical examination, and patient-reported quality of life, bowel, urinary, and sexual function. Results: ECT was successfully delivered in all treated patients. Median procedure time was 23.5 min. Adverse events occurred in all ECT patients, predominantly rectal pain (86%), with one patient hospitalised for pain management. No procedure-related complications were observed. Two ECT patients had R1 resections due to intraoperative perforations. Tumour response was heterogeneous: two patients achieved complete response (TRG1), three achieved partial response (TRG2–3), and one achieved no response; corresponding numbers in the control group were 2, 4, and 2. One ECT patient achieved clinical complete response and entered a watch-and-wait programme. Patient-reported pain worsened transiently after ECT but returned to baseline by 12 weeks post-surgery. Conclusions: ECT is a technically feasible adjunct to neoadjuvant CRT for LARC. However, its efficacy and safety, particularly regarding surgical complications, remain unclear. Larger trials are needed to determine the role of ECT in multimodal neoadjuvant treatment.
Open AccessSafety and Feasibility of Endoscopic-Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: An Exploratory Randomised Clinical Trial
Background: Locally advanced rectal cancer (LARC) has high recurrence rates despite aggressive multimodal treatment with neoadjuvant chemoradiotherapy (CRT) followed by surgery. Electrochemotherapy (ECT), combining electroporation with chemotherapy, has shown safety and feasibility in other malignancies, but its role as an additive neoadjuvant treatment in rectal cancer remains unexplored. Methods: In this parallel-group, randomised safety and feasibility trial, patients with histologically verified LARC who completed neoadjuvant CRT were randomised 1:1 to a single ECT treatment with bleomycin before surgery (n = 8) or standard therapy (n = 8). The primary outcome was safety (amended from the protocol-specified efficacy endpoint after early study termination). Follow-up was scheduled before surgery and at 6 and 12 weeks post-surgery, including adverse events, clinical examination, and patient-reported quality of life, bowel, urinary, and sexual function. Results: ECT was successfully delivered in all treated patients. Median procedure time was 23.5 min. Adverse events occurred in all ECT patients, predominantly rectal pain (86%), with one patient hospitalised for pain management. No procedure-related complications were observed. Two ECT patients had R1 resections due to intraoperative perforations. Tumour response was heterogeneous: two patients achieved complete response (TRG1), three achieved partial response (TRG2–3), and one achieved no response; corresponding numbers in the control group were 2, 4, and 2. One ECT patient achieved clinical complete response and entered a watch-and-wait programme. Patient-reported pain worsened transiently after ECT but returned to baseline by 12 weeks post-surgery. Conclusions: ECT is a technically feasible adjunct to neoadjuvant CRT for LARC. However, its efficacy and safety, particularly regarding surgical complications, remain unclear. Larger trials are needed to determine the role of ECT in multimodal neoadjuvant treatment.
- Open Access
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1916208
Cyclooxygenases in pancreatic ductal adenocarcinoma: are they inflammatory catalysts for tumor growth
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers with a relative 5-year survival around 12%. One of the greatest challenges in PDAC is the frequent systemic dissemination at the time of diagnosis and the dense, fibrotic extracellular matrix that prevents chemotherapeutics and cytotoxic immune cells from entering the tumor stroma. The cyclooxygenase (COX) enzymes and their downstream molecular products play important roles in cancer development and dissemination. The COX isoenzymes are overexpressed in many cancers and inhibition of the COX-2 isoform, and the use of acetylsalicylic acid has recently been demonstrated to reduce cancer recurrence after surgery in subgroups of patients with certain molecular subtypes, such as PI3K mutations, overexpression of vascular growth factors, etc.). COX-2-related pathways are involved in suppressing tumor immunity and promoting stem cell-like properties of cancer cells. Especially in PDAC, targeting the COX enzymes might be of importance in subgroups or as an adjunct as COX-2 is frequently overexpressed and associated with a worse prognosis. Selective COX-2 inhibitors have been demonstrated to reduce tumor growth, invasiveness, and metastasis formation in preclinical trials. This review evaluates existing preclinical and clinical studies investigating the potential for targeting the COX enzymes in PDAC treatment.
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1916208
Open AccessCyclooxygenases in pancreatic ductal adenocarcinoma: are they inflammatory catalysts for tumor growth
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers with a relative 5-year survival around 12%. One of the greatest challenges in PDAC is the frequent systemic dissemination at the time of diagnosis and the dense, fibrotic extracellular matrix that prevents chemotherapeutics and cytotoxic immune cells from entering the tumor stroma. The cyclooxygenase (COX) enzymes and their downstream molecular products play important roles in cancer development and dissemination. The COX isoenzymes are overexpressed in many cancers and inhibition of the COX-2 isoform, and the use of acetylsalicylic acid has recently been demonstrated to reduce cancer recurrence after surgery in subgroups of patients with certain molecular subtypes, such as PI3K mutations, overexpression of vascular growth factors, etc.). COX-2-related pathways are involved in suppressing tumor immunity and promoting stem cell-like properties of cancer cells. Especially in PDAC, targeting the COX enzymes might be of importance in subgroups or as an adjunct as COX-2 is frequently overexpressed and associated with a worse prognosis. Selective COX-2 inhibitors have been demonstrated to reduce tumor growth, invasiveness, and metastasis formation in preclinical trials. This review evaluates existing preclinical and clinical studies investigating the potential for targeting the COX enzymes in PDAC treatment.
- 28 May 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (9) , 1766
Response to Koulaouzidis et al and Sharma et al
- 28 May 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (9) , 1766
Response to Koulaouzidis et al and Sharma et al
- Open Access
- 13 May 2026
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 70 (6) , e70244
Whole Blood Transcriptomic Response to Perioperative Dexamethasone in Total Knee Arthroplasty: A Targeted Panel Analysis
Background: Changes in the transcriptome of immune cells are predictive of clinical outcomes. These effects may be surgery‐specific and possibly modulated by glucocorticoids. We investigated the immune response and the impact of dexamethasone on the response in patients undergoing total knee arthroplasty (TKA). Methods: The transcript levels ( n = 579) in whole blood of 63 patients undergoing TKA and receiving either dexamethasone (DXM, n = 46) or placebo ( n = 17) perioperatively were characterised by the Nanostring nCounter platform and the Immunology V2 panel. Samples were collected before surgery and on the first postoperative day (POD1). Results: Dexamethasone induced differential expression of 113 genes (|log2 fold change| > 0.5, adjusted p ‐value [ p ‐adj] < 0.05). Pathway enrichment analysis using an Over‐Representation Analysis (ORA) indicated an up‐regulation of IL6/JAK‐STAT3‐signalling ( p ‐adj 0.016) and down‐regulation of a pathway related to allograft‐rejection ( p ‐adj 0.032). The immune response itself induced differential expression of 169 genes and ORA only found an allograft rejection pathway significant ( p ‐adj 0.016). Cell type deconvolution indicated that dexamethasone increased the granulocyte fraction (69.6% vs. 73.6%, p ‐adj = 0.005) and reduced B‐ and Plasma‐cell fraction (10.1% vs. 8.4%, p ‐adj = 0.016). The granulocyte fraction on POD1 was significantly different between dexamethasone and placebo‐treated patients (73.6% vs. 70.1%, p ‐adj = 0.048). Conclusions: Perioperative dexamethasone in TKA induced differential expression of genes related to IL6‐JAK/STAT3‐signalling as estimated by the Immunology V2 panel. This, however, is not supported by the literature or a rank‐based interpretation of the most differentially expressed genes and was most likely due to technical reasons. Future studies should focus on broader panels, different techniques or measures leading to fewer exclusions of genes during quality control when seeking to characterise the immune response to TKA and dexamethasone. Editorial Comment: This transcriptomic sub‑study shows that perioperative dexamethasone does not simply suppress, but distinctly reshapes, the early whole‑blood immune response to total knee arthroplasty. However, the study investigated an early postoperative snapshot after a single perioperative dose only. Thus, longitudinal linkage to circulating biomarkers of inflammation and injury as well as clinical outcomes could not be assessed. This study therefore should be regarded as hypothesis‑generating, urging for extended, multi‑modal and outcome‑oriented studies before concluding on the broader clinical effects of perioperative dexamethasone.
- 13 May 2026
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 70 (6) , e70244
Open AccessWhole Blood Transcriptomic Response to Perioperative Dexamethasone in Total Knee Arthroplasty: A Targeted Panel Analysis
Background: Changes in the transcriptome of immune cells are predictive of clinical outcomes. These effects may be surgery‐specific and possibly modulated by glucocorticoids. We investigated the immune response and the impact of dexamethasone on the response in patients undergoing total knee arthroplasty (TKA). Methods: The transcript levels ( n = 579) in whole blood of 63 patients undergoing TKA and receiving either dexamethasone (DXM, n = 46) or placebo ( n = 17) perioperatively were characterised by the Nanostring nCounter platform and the Immunology V2 panel. Samples were collected before surgery and on the first postoperative day (POD1). Results: Dexamethasone induced differential expression of 113 genes (|log2 fold change| > 0.5, adjusted p ‐value [ p ‐adj] < 0.05). Pathway enrichment analysis using an Over‐Representation Analysis (ORA) indicated an up‐regulation of IL6/JAK‐STAT3‐signalling ( p ‐adj 0.016) and down‐regulation of a pathway related to allograft‐rejection ( p ‐adj 0.032). The immune response itself induced differential expression of 169 genes and ORA only found an allograft rejection pathway significant ( p ‐adj 0.016). Cell type deconvolution indicated that dexamethasone increased the granulocyte fraction (69.6% vs. 73.6%, p ‐adj = 0.005) and reduced B‐ and Plasma‐cell fraction (10.1% vs. 8.4%, p ‐adj = 0.016). The granulocyte fraction on POD1 was significantly different between dexamethasone and placebo‐treated patients (73.6% vs. 70.1%, p ‐adj = 0.048). Conclusions: Perioperative dexamethasone in TKA induced differential expression of genes related to IL6‐JAK/STAT3‐signalling as estimated by the Immunology V2 panel. This, however, is not supported by the literature or a rank‐based interpretation of the most differentially expressed genes and was most likely due to technical reasons. Future studies should focus on broader panels, different techniques or measures leading to fewer exclusions of genes during quality control when seeking to characterise the immune response to TKA and dexamethasone. Editorial Comment: This transcriptomic sub‑study shows that perioperative dexamethasone does not simply suppress, but distinctly reshapes, the early whole‑blood immune response to total knee arthroplasty. However, the study investigated an early postoperative snapshot after a single perioperative dose only. Thus, longitudinal linkage to circulating biomarkers of inflammation and injury as well as clinical outcomes could not be assessed. This study therefore should be regarded as hypothesis‑generating, urging for extended, multi‑modal and outcome‑oriented studies before concluding on the broader clinical effects of perioperative dexamethasone.
- Open Access
- 18 April 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
The impact of statins on prognostic outcomes in patients with non-metastatic solid cancers: a systematic review and meta-analysis
Background Statins are commonly prescribed low-density lipoprotein-lowering drugs that have been used in patients with cancer due to their pleiotropic effects. In this paper, the association between statin use and prognostic outcomes was examined in patients with non-metastatic solid cancer. Methods In accordance with the PRISMA guidelines, a systematic review of the literature was conducted, and meta-analyses of time-to-event outcomes were performed. The literature search was designed using the Participants, Intervention, Comparator, and Outcome (PICO) framework. The search was completed across three different databases: PubMed, The Cochrane Library, and Web of Science. Studies investigating the impact of statin use versus no statin use on oncological survival measures in patients with non-metastatic solid cancers were eligible for inclusion. The outcomes of interest were overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS). Furthermore, the impact of statin use on the tumor microenvironment was an outcome of interest. The risk of bias was assessed using the Newcastle-Ottawa Scale and the quality of the cumulative evidence was evaluated using the modified GRADE approach. Findings A total of 4,131 articles were title and abstract screened of which 106 articles were included in the systematic review and 90 articles in the meta-analysis. The total number of included patients in the meta-analysis was 472,004 Statin use in patients with non-metastatic solid cancer was significantly associated with improved OS (hazard ratio (HR) = 0.84, 95% confidence interval (CI): 0.80–0.88, I2: 89%), RFS (HR = 0.78, 95% CI: 0.69–0.88, I2: 84%), and CSS (HR = 0.86, 95% CI: 0.81–0.91, I2: 81%). Statin use showed significantly improved OS in patients with gastrointestinal cancer (HR = 0.79, 95% CI: 0.72–0.87, I2: 88%), urological cancer (HR = 0.85, 95% CI: 0.77–0.94, I2: 86%), and gynecological cancer (HR = 0.84, 95% CI: 0.74–0.95, I2: 0%). Conclusions. Statin therapy was associated with improved survival outcomes in patients with non-metastatic solid cancer, especially in gastrointestinal, urological and gynecological cancers.
- 18 April 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessThe impact of statins on prognostic outcomes in patients with non-metastatic solid cancers: a systematic review and meta-analysis
Background Statins are commonly prescribed low-density lipoprotein-lowering drugs that have been used in patients with cancer due to their pleiotropic effects. In this paper, the association between statin use and prognostic outcomes was examined in patients with non-metastatic solid cancer. Methods In accordance with the PRISMA guidelines, a systematic review of the literature was conducted, and meta-analyses of time-to-event outcomes were performed. The literature search was designed using the Participants, Intervention, Comparator, and Outcome (PICO) framework. The search was completed across three different databases: PubMed, The Cochrane Library, and Web of Science. Studies investigating the impact of statin use versus no statin use on oncological survival measures in patients with non-metastatic solid cancers were eligible for inclusion. The outcomes of interest were overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS). Furthermore, the impact of statin use on the tumor microenvironment was an outcome of interest. The risk of bias was assessed using the Newcastle-Ottawa Scale and the quality of the cumulative evidence was evaluated using the modified GRADE approach. Findings A total of 4,131 articles were title and abstract screened of which 106 articles were included in the systematic review and 90 articles in the meta-analysis. The total number of included patients in the meta-analysis was 472,004 Statin use in patients with non-metastatic solid cancer was significantly associated with improved OS (hazard ratio (HR) = 0.84, 95% confidence interval (CI): 0.80–0.88, I2: 89%), RFS (HR = 0.78, 95% CI: 0.69–0.88, I2: 84%), and CSS (HR = 0.86, 95% CI: 0.81–0.91, I2: 81%). Statin use showed significantly improved OS in patients with gastrointestinal cancer (HR = 0.79, 95% CI: 0.72–0.87, I2: 88%), urological cancer (HR = 0.85, 95% CI: 0.77–0.94, I2: 86%), and gynecological cancer (HR = 0.84, 95% CI: 0.74–0.95, I2: 0%). Conclusions. Statin therapy was associated with improved survival outcomes in patients with non-metastatic solid cancer, especially in gastrointestinal, urological and gynecological cancers.
- Top Cited Papers
- 21 March 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (9) , 1594-1609
Impact of beta-blockers on prognostic outcomes in solid cancers: a systematic review and meta-analysis
Background: Beta-blockers are conventionally prescribed for cardiovascular indications and have potential for repurposing in oncology as adrenergic signaling promotes cancer progression. This systematic review and meta-analysis evaluated whether beta-blocker use is associated with improved survival outcomes in patients with all stages of solid cancer. Methods: This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines using a predefined (participants, intervention, comparator, and outcome) framework. Four databases (PubMed, Embase, Cochrane Library, and Web of Science) were searched. Eligible studies compared beta-blocker users with nonusers and reported survival outcomes in patients with solid cancer. Outcomes included overall survival, cancer-specific survival, disease-free survival, progression-free survival, and recurrence-free survival. Risk of bias was assessed using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias 2 tool. Certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: A total of 5122 articles were screened; 94 articles were included in the systematic review and 84 in the meta-analysis comprising 603 827 patients. Beta-blocker use in patients with solid cancers was associated with statistically improved overall survival (hazard ratio [HR] = 0.88, 95% confidence interval [CI] = 0.80 to 0.96) and progression-free survival (HR = 0.82, 95% CI = 0.69 to 0.97). The greatest effects on overall survival were observed in patients with gastrointestinal (HR = 0.84, 95% CI = 0.72 to 0.98), lung (HR = 0.84, 95% CI = 0.71 to 0.99), and skin cancers (HR = 0.81, 95% CI = 0.73 to 0.89). Effects appeared stronger with postdiagnostic exposure, and in certain cancer subtypes, however, heterogeneity and the observational nature of most included studies warrant cautious interpretation. Conclusion: Beta-blocker use was associated with improved overall and progression-free survival in patients with solid cancers.
- 21 March 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (9) , 1594-1609
Top Cited PapersImpact of beta-blockers on prognostic outcomes in solid cancers: a systematic review and meta-analysis
Background: Beta-blockers are conventionally prescribed for cardiovascular indications and have potential for repurposing in oncology as adrenergic signaling promotes cancer progression. This systematic review and meta-analysis evaluated whether beta-blocker use is associated with improved survival outcomes in patients with all stages of solid cancer. Methods: This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines using a predefined (participants, intervention, comparator, and outcome) framework. Four databases (PubMed, Embase, Cochrane Library, and Web of Science) were searched. Eligible studies compared beta-blocker users with nonusers and reported survival outcomes in patients with solid cancer. Outcomes included overall survival, cancer-specific survival, disease-free survival, progression-free survival, and recurrence-free survival. Risk of bias was assessed using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias 2 tool. Certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: A total of 5122 articles were screened; 94 articles were included in the systematic review and 84 in the meta-analysis comprising 603 827 patients. Beta-blocker use in patients with solid cancers was associated with statistically improved overall survival (hazard ratio [HR] = 0.88, 95% confidence interval [CI] = 0.80 to 0.96) and progression-free survival (HR = 0.82, 95% CI = 0.69 to 0.97). The greatest effects on overall survival were observed in patients with gastrointestinal (HR = 0.84, 95% CI = 0.72 to 0.98), lung (HR = 0.84, 95% CI = 0.71 to 0.99), and skin cancers (HR = 0.81, 95% CI = 0.73 to 0.89). Effects appeared stronger with postdiagnostic exposure, and in certain cancer subtypes, however, heterogeneity and the observational nature of most included studies warrant cautious interpretation. Conclusion: Beta-blocker use was associated with improved overall and progression-free survival in patients with solid cancers.
- Open Access
- 28 January 2026
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 41 (1) , 49
Surgical outcomes in pelvic reconstruction using robot-assisted rectus abdominis muscle flaps: a systematic review
Purpose Pelvic cancer resections increase the risk of pelvic dead space, which increases the risk of postoperative complications. Robot-assisted pelvic reconstruction surgeries are a novel approach that may be beneficial, but it is unclear what impact it has on surgical outcomes in pelvic reconstruction with rectus abdominis muscle flaps. The aim of the study was to systematically review the surgical outcomes of robot-assisted pelvic reconstruction using rectus abdominis muscle flaps in patients with any pelvic cancers. Method A systematic search of the literature was conducted in PubMed, Web of Science, Cochrane Library, and Embase following the PRISMA guidelines, and the final search on all databases was performed on the 13th of May 2024. Studies reporting surgical outcomes of robot-assisted pelvic reconstruction with rectus abdominis muscle flaps were eligible based on predefined criteria. Two reviewers independently screened the literature, extracted data, and assessed risk of bias of included studies. Results Five studies, including 143 patients in total, met the inclusion criteria, comprising two retrospective cohort studies and three case series. Of these, 36 patients underwent robot-assisted pelvic reconstruction using rectus abdominis flaps. All studies reported wound complications, which were lower in the robot-assisted groups compared to open surgery groups. One study reported shorter length of stay. Two studies reported better visualization and avoidance of excessive blood loss when performing robot-assisted surgery. Conclusions Early reports indicate that robot-assisted surgery with flaps in pelvic reconstruction could improve postoperative outcomes. Further research should investigate the potential benefits through larger and controlled patient groups.
- 28 January 2026
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 41 (1) , 49
Open AccessSurgical outcomes in pelvic reconstruction using robot-assisted rectus abdominis muscle flaps: a systematic review
Purpose Pelvic cancer resections increase the risk of pelvic dead space, which increases the risk of postoperative complications. Robot-assisted pelvic reconstruction surgeries are a novel approach that may be beneficial, but it is unclear what impact it has on surgical outcomes in pelvic reconstruction with rectus abdominis muscle flaps. The aim of the study was to systematically review the surgical outcomes of robot-assisted pelvic reconstruction using rectus abdominis muscle flaps in patients with any pelvic cancers. Method A systematic search of the literature was conducted in PubMed, Web of Science, Cochrane Library, and Embase following the PRISMA guidelines, and the final search on all databases was performed on the 13th of May 2024. Studies reporting surgical outcomes of robot-assisted pelvic reconstruction with rectus abdominis muscle flaps were eligible based on predefined criteria. Two reviewers independently screened the literature, extracted data, and assessed risk of bias of included studies. Results Five studies, including 143 patients in total, met the inclusion criteria, comprising two retrospective cohort studies and three case series. Of these, 36 patients underwent robot-assisted pelvic reconstruction using rectus abdominis flaps. All studies reported wound complications, which were lower in the robot-assisted groups compared to open surgery groups. One study reported shorter length of stay. Two studies reported better visualization and avoidance of excessive blood loss when performing robot-assisted surgery. Conclusions Early reports indicate that robot-assisted surgery with flaps in pelvic reconstruction could improve postoperative outcomes. Further research should investigate the potential benefits through larger and controlled patient groups.
- Open Access
- 4 December 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Tumor characteristics impact prognosis in deficient mismatch repair/microsatellite instability-high localized colorectal cancer—a systematic review and meta-analysis
Background: Deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) tumors constitute ∼15% of localized colorectal cancers (CRCs). Prognostic biomarkers such as tumor-infiltrating lymphocytes (TILs) and BRAF and KRAS mutations may guide personalized treatment for these patients, and this systematic review and meta-analysis aimed to evaluate their impact on survival outcomes. Methods: Literature searches were conducted across PubMed, Embase, Cochrane Library, and Web of Science, including studies published between 2004 and 2023. The primary outcomes were overall survival (OS), disease-free survival (DFS), and cancer-specific survival. The risk of bias was assessed using the Newcastle-Ottawa Scale, and the certainty of evidence using the GRADE approach. Results: The literature search yielded 5636 articles. Fifty-four studies were included in the systematic review and 31 studies in the meta-analysis, totaling 4551 patients. High TIL density was significantly associated with improved OS (hazard ratio [HR] = 0.39, 95% CI = 0.17 to 0.89) and DFS (HR = 0.45, 95% CI = 0.29 to 0.71). BRAF and KRAS mutations were seen in 52% and 34% of patients, respectively, and were associated with poorer OS (HR = 1.43, 95% CI = 1.13 to 1.80 and HR = 1.30, 95% CI = 1.09 to 1.54, respectively). Quality of evidence was moderate to high across all exposures and outcomes. Conclusion: High infiltration of TILs correlated with improved OS and DFS, whereas BRAF and KRAS mutations were associated with worse OS in patients with localized dMMR/MSI-H CRC. These findings highlight the potential utility of biomarkers for improving prognostic assessment and personalizing management in dMMR CRC.
- 4 December 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Open AccessTumor characteristics impact prognosis in deficient mismatch repair/microsatellite instability-high localized colorectal cancer—a systematic review and meta-analysis
Background: Deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) tumors constitute ∼15% of localized colorectal cancers (CRCs). Prognostic biomarkers such as tumor-infiltrating lymphocytes (TILs) and BRAF and KRAS mutations may guide personalized treatment for these patients, and this systematic review and meta-analysis aimed to evaluate their impact on survival outcomes. Methods: Literature searches were conducted across PubMed, Embase, Cochrane Library, and Web of Science, including studies published between 2004 and 2023. The primary outcomes were overall survival (OS), disease-free survival (DFS), and cancer-specific survival. The risk of bias was assessed using the Newcastle-Ottawa Scale, and the certainty of evidence using the GRADE approach. Results: The literature search yielded 5636 articles. Fifty-four studies were included in the systematic review and 31 studies in the meta-analysis, totaling 4551 patients. High TIL density was significantly associated with improved OS (hazard ratio [HR] = 0.39, 95% CI = 0.17 to 0.89) and DFS (HR = 0.45, 95% CI = 0.29 to 0.71). BRAF and KRAS mutations were seen in 52% and 34% of patients, respectively, and were associated with poorer OS (HR = 1.43, 95% CI = 1.13 to 1.80 and HR = 1.30, 95% CI = 1.09 to 1.54, respectively). Quality of evidence was moderate to high across all exposures and outcomes. Conclusion: High infiltration of TILs correlated with improved OS and DFS, whereas BRAF and KRAS mutations were associated with worse OS in patients with localized dMMR/MSI-H CRC. These findings highlight the potential utility of biomarkers for improving prognostic assessment and personalizing management in dMMR CRC.
- 1 October 2025
- Published by Springer Nature
- p. 545-577
Cancer Immunodiagnosis in Upper Gastrointestinal Cancers
- 1 October 2025
- Published by Springer Nature
- p. 545-577
Cancer Immunodiagnosis in Upper Gastrointestinal Cancers
- Open Access
Long-Term Oncological Outcomes of Granulocyte Colony-Stimulating Factor (G-CSF) Treatment in Gastrointestinal Cancers: A Systematic Review and Meta-Analysis
Background: Granulocyte-colony stimulating factor (G-CSF) prophylaxis is widely used in gastrointestinal (GI) cancers. The use of G-CSF in GI cancers has not previously been investigated systematically in a meta-analysis. Thus, we systematically reviewed the literature to describe the G-CSF use and potential influence on long-term oncological outcomes in GI cancers. Method: The literature search of this systematic review and meta-analysis was conducted in PubMed, Embase, Cochrane Library and Web of Science. The PRISMA-P guidelines were followed. Studies that reported data on patients with GI cancers undergoing oncological treatment with G-CSF prophylaxis were included. Outcomes of interest were overall survival (OS), progression-free survival (PFS) and adverse events (AE), specifically neutropenia grade III/IV. A time-to-event random-effects meta-analysis was conducted. Risk of bias was assessed using the Newcastle–Ottawa Scale and the Cochrane Risk of Bias Tool for Randomized Controlled Trials (RoB) tool. Findings: In total, 2452 articles were screened for eligibility. Ultimately, 13 studies were included with a total patient number of 2673. The included studies indicated a positive association between OS and G-CSF prophylaxis (HR 0.72, 95% CI: 0.56–0.91, I2: 54%, low quality evidence). No significant relation between G-CSF use and PFS was found in the pooled analyses (HR 0.74, 95% CI: 0.51–1.08, I2: 73%, moderate quality evidence). However, a positive effect of G-CSF use was found in the retrospective cohorts reporting data on PFS (HR 0.50, 95% CI: 0.32–0.77, I2: 0%). A marked drop in neutropenia grade III/IV rates was observed in patients treated with G-CSF (risk ratio (RR) 0.46, 95% CI: 0.28–0.77, I2: 72%, high quality evidence). Interpretation: G-CSF prophylaxis provides a reduction in neutropenia grade III/IV in patients with GI cancers (high level of certainty) and a favorable OS (low certainty), while PFS is unaffected (moderate certainty). Studies on PFS and G-CSF use are nonetheless limited.
Open AccessLong-Term Oncological Outcomes of Granulocyte Colony-Stimulating Factor (G-CSF) Treatment in Gastrointestinal Cancers: A Systematic Review and Meta-Analysis
Background: Granulocyte-colony stimulating factor (G-CSF) prophylaxis is widely used in gastrointestinal (GI) cancers. The use of G-CSF in GI cancers has not previously been investigated systematically in a meta-analysis. Thus, we systematically reviewed the literature to describe the G-CSF use and potential influence on long-term oncological outcomes in GI cancers. Method: The literature search of this systematic review and meta-analysis was conducted in PubMed, Embase, Cochrane Library and Web of Science. The PRISMA-P guidelines were followed. Studies that reported data on patients with GI cancers undergoing oncological treatment with G-CSF prophylaxis were included. Outcomes of interest were overall survival (OS), progression-free survival (PFS) and adverse events (AE), specifically neutropenia grade III/IV. A time-to-event random-effects meta-analysis was conducted. Risk of bias was assessed using the Newcastle–Ottawa Scale and the Cochrane Risk of Bias Tool for Randomized Controlled Trials (RoB) tool. Findings: In total, 2452 articles were screened for eligibility. Ultimately, 13 studies were included with a total patient number of 2673. The included studies indicated a positive association between OS and G-CSF prophylaxis (HR 0.72, 95% CI: 0.56–0.91, I2: 54%, low quality evidence). No significant relation between G-CSF use and PFS was found in the pooled analyses (HR 0.74, 95% CI: 0.51–1.08, I2: 73%, moderate quality evidence). However, a positive effect of G-CSF use was found in the retrospective cohorts reporting data on PFS (HR 0.50, 95% CI: 0.32–0.77, I2: 0%). A marked drop in neutropenia grade III/IV rates was observed in patients treated with G-CSF (risk ratio (RR) 0.46, 95% CI: 0.28–0.77, I2: 72%, high quality evidence). Interpretation: G-CSF prophylaxis provides a reduction in neutropenia grade III/IV in patients with GI cancers (high level of certainty) and a favorable OS (low certainty), while PFS is unaffected (moderate certainty). Studies on PFS and G-CSF use are nonetheless limited.